Hypertension drug approved for pediatric patients

Article

Daiichi-Sankyo's agent olmesartan (Benicar) has been approved by the FDA for the treatment of hypertension in patients aged 6 to 16 years.

Daiichi-Sankyo's agent olmesartan (Benicar) has been approved by the FDA for the treatment of hypertension in patients aged 6 to 16 years.

The recommended starting dose is 10 mg once daily for patients who weigh 20 kg to less than 35 kg and 20 mg once daily for patients who weigh at least 35 kg. After 2 weeks, the dose can be increased to a maximum of 20 mg once daily in those who weigh less than 35 kg and 40 mg once daily in those who weigh at least 35 kg.

Recent Videos
Stephanie Chao, MD
Feasibility of ambulatory blood pressure monitoring in primary care | Carissa Baker-Smith, MD, MPH
Tina Tan, MD
Camille Walker CPNP-PC, MSN, CPNP Sacheen D. Harris MSN, CPNP-PC
Danielle Van Damme, DNP, CPNP-AC
Karen Y. Capusan, DNP, CPNP-PC
Discussion: AAP's opioid for acute pain clinical practice guideline with Jessica Spruit, DNP
Bobbie Monaco, MSN, CPNP-PC
Measles outbreaks: 223 cases reported in Texas | Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
© 2025 MJH Life Sciences

All rights reserved.